Dear ,

In the current issue of the OncoWuXi Newsletter, we would like to share with you our updates on genetically engineered Ba/F3 cell lines and corresponding in vivo/in vitro validation data. Other interesting topics covered in this issue include our in vivo efficacy platform for bispecific antibodies, and CLDN18.2 targeted in vivo models.

OncoWuXi Newsletter will continue to keep you up-to-date with our recent progress in cancer research. As part of WuXi AppTec Research Service Division (RSD), our topnotch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.

Translational Oncology
(1)    Engineered Ba/F3 cell lines with ALK mutations and validation data
  • Ba/F3-EML4-ALK
  • Ba/F3-EML4-ALK-L1196M
  • Ba/F3-EML4-ALK-C1156Y
  • Ba/F3-EML4-ALK-G1202R/L1196M
  • Ba/F3-EML4-ALK-G1202R
  • Validated with Crizotinib, Brigatinib, Lorlatinib, Alectinib , Ceritinib and Entrectinib in vitro or in vivo

(2)    Engineered Ba/F3 cell lines with EGFR mutations and validation data
  • Ba/F3-EGFR-exon 19 del/T790M
  • Ba/F3-EGFR-exon 19 del/T790M/C797S
  • Ba/F3-EGFR-L858R/T790M/C797S
  • Ba/F3-EGFR-exon 19 del/C797S
  • Ba/F3-EGFR-L858R/T790M
  • Ba/F3-EGFR-L858R/C797S
  • Ba/F3-EGFR-L858R
  • Ba/F3-EGFR-exon 19 deletion
  • Ba/F3-EGFR-exon 20_V769_D770insASV
  • Ba/F3-EGFR-exon 20_D770_N771insSVD
  • Ba/F3-EGFR-exon 20_H773_V774insNPH
  • Validated with Gefitinib, Erlotinib, Dacomitinib, Brigatinib, Afatinib, Osimertinib, and Poziotinib in vitro or in vivo

(3)    Engineered Ba/F3 cell lines with TRK mutations and validation data
  • Ba/F3-ETV6-NTRK3-G623R
  • Ba/F3-ETV6-NTRK3-G696A
  • Ba/F3-ETV6-NTRK3-WT
  • Ba/F3-TPM3-NTRK1-G595R
  • Ba/F3-TPM3-NTRK1-G667C
  • Ba/F3-TPM3-NTRK1-WT
  • Ba/F3-LMNA-NTRK1-G595R
  • Ba/F3-LMNA-NTRK1-G667C
  • Validated with LOXO-101 and Entrectinib both in vitro and in vivo

(1)    Background of bispecific antibodies

(2)    Platform for BsAbs in vivo efficacy study
  • Introduction of co-inoculation hPBMC humanized models
  • Workflow of BsAbs in vivo efficacy study
  • Case study: anti-CD3/anti-X bsAbs screening in Raji co-inoculation hPBMC humanized model
  • 21 co-inoculation hPBMC humanized models

(3)    Platform for BsAbs MOA study
  • Binding affinity assay
  • T cell activation assay
  • Tumor suppression assay
  • ADCC and CDC assay
  • FACS-based immuno-profiling
  • Cytokine detection assay

Targeted Oncology
CLDN18.2 Targeted In Vivo Models
(1)    CLDN18.2 background as a drug target
  • CLDN18.2 biology
  • Introduction of CLDN18.2 targeted antibody

(2)    CLDN18.2 related CDX models
  • NUGC4 gastric cancer CDX model, validated with IMBA362

(3)    Engineered cell line/model of MIA PaCa-2 overexpressing human CLDN18.2

(4)    CLDN18.2 related PDX models
  • 8 pancreatic cancer and 5 gastric cancer PDX models with CLDN18 overexpression

We sincerely appreciate your interest, time and support, and would like to hear your feedback so we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.

Best regards,
WuXi AppTec OncoWuXi Team